Foot-and-Mouth Disease Virus Lacking the Leader Protein and Containing Two Negative DIVA Markers (FMDV LL3B3D A<sub>24</sub>) Is Highly Attenuated in Pigs
Inactivated whole-virus vaccines are widely used for the control of foot-and-mouth disease (FMD). Their production requires the growth of large quantities of virulent FMD virus in biocontainment facilities, which is expensive and carries the risk of an inadvertent release of virus. Attenuated recomb...
Autori principali: | Michael Eschbaumer, Veronika Dill, Jolene C. Carlson, Jonathan Arzt, Carolina Stenfeldt, Peter W. Krug, John M. Hardham, Jacob E. Stegner, Luis L. Rodriguez, Elizabeth Rieder |
---|---|
Natura: | Articolo |
Lingua: | English |
Pubblicazione: |
MDPI AG
2020-02-01
|
Serie: | Pathogens |
Soggetti: | |
Accesso online: | https://www.mdpi.com/2076-0817/9/2/129 |
Documenti analoghi
Documenti analoghi
-
Novel Foot-and-Mouth Disease Vaccine Platform: Formulations for Safe and DIVA-Compatible FMD Vaccines With Improved Potency
di: John M. Hardham, et al.
Pubblicazione: (2020-09-01) -
Exchange of C-Terminal Variable Sequences within Morbillivirus Nucleocapsid Protein Are Tolerated: Development and Evaluation of Two Marker (DIVA) Vaccines (Sungri/96 DIVA, Nigeria/75/1 DIVA) against PPR
di: Muneeswaran Selvaraj, et al.
Pubblicazione: (2021-11-01) -
The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves
di: Gaetano Federico Ronchi, et al.
Pubblicazione: (2024-11-01) -
Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever
di: Tinka Jelsma, et al.
Pubblicazione: (2021-05-01) -
Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins
di: Anne Balkema-Buschmann, et al.
Pubblicazione: (2022-05-01)